This study highlights four key findings regarding the real-world use of PCSK9-mAb therapy in high-risk dyslipidemia patients: First, treatment persistence was high, with over 90% of patients remaining on PCSK9-mAb therapy since treatment initiation over a 3-year period. Here, PCSK9 is linked to metabolic syndrome.